Isabelle Gilloteau
Novartis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Isabelle Gilloteau.
BMC Health Services Research | 2017
Steven R. Feldman; Haijun Tian; Isabelle Gilloteau; Patrick Mollon; Meng Shu
BackgroundPsoriasis is a multifactorial, inflammatory, skin disease associated with various comorbidities. The cost of those comorbidities is not well characterized. The present study assesses the incremental burden of comorbidities on healthcare resource utilization, direct costs and indirect costs associated with short-term disabilities among patients with psoriasis in the United States.MethodsA retrospective, U.S. cohort analysis was conducted using a large claims database. Adult psoriasis patients with at least two diagnoses of psoriasis during the years 2010 and 2011 (one psoriasis diagnosis had to happen in the year 2010) and with continuous enrollment of medical and pharmacy benefits in the years 2010 and 2011 were included. Psoriasis patients were categorized and compared according to the presence or absence of pre-selected comorbidities in the year 2010. Adjusted annual direct (costs associated with outpatient, emergency room, and inpatient claims, and outpatient pharmacy claims) and indirect costs (short-term disabilities) was assessed in patients with and without comorbidities using a regression analysis, controlling for age, gender, and psoriasis severity in year 2010.ResultsIn total, 56,406 patients (mean [SD]) age, 51.6 [14.6] years) were included in the analysis. The most prevalent comorbidities were hypertension (34.3%), hyperlipidemia (33.5%), cardiovascular disease (17.7%), diabetes (14.2%), and psoriatic arthritis (9.9%). Psoriasis patients with comorbidities used more healthcare resources than those without comorbidities. The incidence rate ratio (IRR) (95% CI) for patients with cardiovascular disease was 1.5 (1.4 − 1.5) for outpatient visits, 2.6 (2.4 − 2.8) for hospitalizations, and 2.3 (2.2 − 2.5) for ER visits, showing higher IRRs across all three types of resource use. The mean annual adjusted direct cost differences (i.e., incremental adjusted costs) in psoriasis patients with and without comorbidities were
Journal of The European Academy of Dermatology and Venereology | 2017
Matthias Augustin; J Vietri; Haijun Tian; Isabelle Gilloteau
9914.3,
Journal of The European Academy of Dermatology and Venereology | 2017
Andrew Blauvelt; K. Reich; Stephanie Mehlis; Francisco Vanaclocha; Howard Sofen; W Abramovits; Yang Zhao; Isabelle Gilloteau; E Davenport; Nicole Williams; Adriana Guana; Stephen K. Tyring
8386.5, and
Journal of The American Academy of Dermatology | 2017
Bruce E. Strober; Alice B. Gottlieb; Bintu Sherif; Patrick Mollon; Isabelle Gilloteau; Lori McLeod; Todd Fox; Margaret Mordin; Ari Gnanasakthy; Charis Papavassilis; Mark Lebwohl
8275.1 for psoriatic arthritis, peripheral vascular disease, and cardiovascular disease, respectively. The mean annual incremental adjusted indirect costs of short-term disabilities were
Journal of Dermatological Treatment | 2017
Boni E. Elewski; Lluís Puig; Margaret Mordin; Isabelle Gilloteau; Bintu Sherif; Todd Fox; Ari Gnanasakthy; Charis Papavassilis; Bruce E. Strober
1333,
Journal of The European Academy of Dermatology and Venereology | 2018
C.E.M. Griffiths; Matthias Augustin; Luigi Naldi; Ricardo Romiti; E Guevara-Sangines; T Howe; G. Pietri; Isabelle Gilloteau; C. Richardson; Haijun Tian; Sj Jo
1195,
Journal of The European Academy of Dermatology and Venereology | 2018
Matthias Augustin; Doreen McBride; Isabelle Gilloteau; Caitriona O'Neill; Katja Neidhardt; Christopher N. Graham
994.9, and
Journal of The European Academy of Dermatology and Venereology | 2018
Richard B. Warren; A Halliday; Christopher N. Graham; Isabelle Gilloteau; LaStella Miles; Doreen McBride
996.6 for cerebrovascular disease, obesity, peripheral vascular disease, and depression, respectively.ConclusionThe presence of comorbidities was associated with higher healthcare resource utilization and costs among patients with psoriasis.
Journal of Managed Care Pharmacy | 2018
Steven R. Feldman; Yang Zhao; Isabelle Gilloteau; Christopher N. Graham; LaStella Miles; Doreen McBride; Vivian Herrera
Moderate‐to‐severe psoriasis is associated with reduced health‐related quality of life (HRQoL). Individuals with psoriasis are at increased risk for other medical conditions, but little information quantifies the incremental burden of psoriasis‐associated comorbidity among European adults, and data have generally been limited to clinical samples.
Journal of Dermatological Treatment | 2018
A. Bewley; Cristiana Miglio; Haijun Tian; Isabelle Gilloteau; Joannah Whitehead; Ruben Hermans
Psoriasis can greatly impact patients’ lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin‐17A, has demonstrated good efficacy and safety in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response.